Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 15/20 | 0.53 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.50 |
| ▸ | HNF4A | P41235 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24272034 | 0.94 | GPR52 (0.50) | GPR52ACMSDHNF4A | |
| SCHEMBL24271968 | 0.90 | ACMSD (0.49) | GPR52ACMSDHNF4AXDHSLC22A12 | |
| SCHEMBL24271871 | 0.90 | GPR52 (0.58) | GPR52SMN1; SMN2 | |
| SCHEMBL24271730 | 0.90 | PDK1 (0.49) | GPR52ACMSDHNF4AXDHSLC22A12 | |
| SCHEMBL24271870 | 0.89 | GPR52 (0.48) | GPR52ACMSDHNF4AXDHSLC22A12 | |
| SCHEMBL24271743 | 0.89 | ACMSD (0.49) | GPR52ACMSDHNF4AXDHSLC22A12 | |
| SCHEMBL24271874 | 0.88 | XDH (0.57) | GPR52XDHSLC22A12 | |
| SCHEMBL24271957 | 0.88 | GPR52 (0.51) | GPR52ACMSDHNF4AXDHSLC22A12 | |
| SCHEMBL24272027 | 0.88 | ACMSD (0.44) | GPR52ACMSDHNF4AXDHSLC22A12 | |
| SCHEMBL24272025 | 0.87 | GPR52 (0.46) | GPR52ACMSDHNF4AXDHSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION | 2023-11-02 | — | — | US | disclosed |
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION | 2023-11-02 | — | — | US | disclosed |
| WO-2022056447-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | BPGM, PGAM1, PGM2 | GPR52 2667/4885ACMSD 253/4885HNF4A 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.